Cargando…
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with driver gene mutations arise in the background of clonal hematopoiesis (CH) under the positive selective pressure of chemo- and radiation therapies. Uncovering the exposure relationships that provide selective adv...
Autores principales: | Sperling, Adam S., Guerra, Veronica A., Kennedy, James A., Yan, Yuanqing, Hsu, Joanne I., Wang, Feng, Nguyen, Andrew T., Miller, Peter G., McConkey, Marie E., Quevedo Barrios, Vanessa A., Furudate, Ken, Zhang, Linda, Kanagal-Shamanna, Rashmi, Zhang, Jianhua, Little, Latasha, Gumbs, Curtis, Daver, Naval, DiNardo, Courtney D., Kadia, Tapan, Ravandi, Farhad, Kantarjian, Hagop, Garcia-Manero, Guillermo, Futreal, P. Andrew, Ebert, Benjamin L., Takahashi, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837415/ https://www.ncbi.nlm.nih.gov/pubmed/35512188 http://dx.doi.org/10.1182/blood.2021014956 |
Ejemplares similares
-
Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021) -
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016) -
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019) -
P509: THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.
por: Swaminathan, Mahesh, et al.
Publicado: (2023) -
P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)